The MiruTyton test was carried out with 1600 birds, 200 per treatment (100 male and 100 female) with 10 birds per cage. The MiruTyton doses in drinker were 250, 500, 1000ppm of net butyrate per treatment, while in solid feed they were 500, 1000, 2000 and 4000ppm. Body weight, feed intake and mortality were measured on days 0,14, 21, 28 and 42, while measurements on GIT histology and Campylobacter log10 per gram and Salmonella incidence in cecum and fecal samples were taken on day 42.
Cargill and WDL have recently announced an off-take agreement for WDL’s premium Single Cell Protein, ProTyton which is a co-product of MiruTyton. WDL has developed and scaled up the anaerobic fermentation process for these products, and will be producing them in the MRE ethanol plant in Sutherland, NE.
“We are happy to announce these results, which were demonstrated through a close collaboration with industry experts and an independent testing lab,” said WDL’s CEO, Bryan Tracy. “Because MiruTyton is a liquid, we envision accurate and economical administration, and since it has a co-product that shares its production costs, it has pricing flexibility,” said Tracy. “We thus expect MiruTyton, also natural product, to have a positive impact on the industry, and are actively seeking a partner to distribute globally.”
WDL is a biotech company re-focused in recent months on animal health and nutrition The company has invented a proprietary process, ProtocolB, for the isolation, selection and cultivation of microbiome-derived organisms, and developed MixoFerm, a fermentation technology that consumes sugar and gases, thus increasing product yield in industrial fermentation.